Shanghai Shangyao Chinese-Western Pharmaceutical Co., Ltd

Primary Objective: This study aimed to investigate the pharmacokinetic characteristics of baricitinib tablets (2 mg) manufactured by Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd., after a single oral fasting administration. Baricitinib tablets (Ailemin®, 2 mg) manufactured by Lilly del Caribe, Inc. were used as the reference formulation. The pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two formulations were compared to evaluate their human bioequivalence. Secondary Objective: To evaluate the safety of the test formulation and the reference formulation in healthy Chinese participants under fasting conditions.

Primary Objective: To compare the extent and rate of absorption of the test formulation, upadacitinib extended-release tablets (15 mg) provided by Shanghai Pharma Zhongxi Pharmaceutical Co., Ltd., and the reference formulation, upadacitinib extended-release tablets (RINVOQ®; 15 mg) licensed by AbbVie Deutschland GmbH & Co. KG, in healthy Chinese subjects under fasting and fed conditions, and to evaluate the bioequivalence of the two formulations. Secondary Objective: To evaluate the safety of the test formulation and the reference formulation in healthy Chinese subjects under fasting and fed conditions.

The main purpose of single-dose administration is to investigate the pharmacokinetic (PK) characteristics and PK ethnic sensitivity of eslicarbazepine acetate tablets at different dose levels in Chinese healthy subjects under fasting conditions. The main purpose of multiple-dose administration is to investigate the pharmacokinetic (PK) characteristics of eslicarbazepine acetate tablets at the same dose in Chinese healthy subjects under fasting conditions.